Skip to main content
Retour
LVZPF logo

Livzon Pharmaceutical Group Inc.

Qualité des données : 100%
Suracheté
LVZPF
OTC Healthcare Drug Manufacturers - Specialty & Generic
5,22 €
0,00 € (0,00%)
Cap. Boursière : 6,06B
Fourchette du Jour
4,35 € 5,22 €
Fourchette 52 Semaines
3,43 € 5,22 €
Volume
1
Moyenne 50J / 200J
5,22 € / 4,66 €
Clôture Précédente
5,22 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 2,9 0,4
P/B 0,4 2,9
ROE % 14,8 3,7
Net Margin % 17,5 3,9
Rev Growth 5Y % 2,9 10,0
D/E 0,3 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 2,66 €
2,49 € – 2,76 €
13 B 1
FY2026 2,44 €
2,28 € – 2,54 €
12 B 1

Points Clés

Revenue grew 2,94% annually over 5 years — modest growth
ROE of 14,77% — decent returns on equity
Net margin of 17,45% shows strong profitability
Debt/Equity of 0,28 — conservative balance sheet
Generating 2,41B in free cash flow
P/E of 2,94 — trading at a low valuation

Croissance

Revenue Growth (5Y)
2,94%
Revenue (1Y)-4,97%
Earnings (1Y)5,50%
FCF Growth (3Y)14,65%

Qualité

Return on Equity
14,77%
ROIC11,99%
Net Margin17,45%
Op. Margin24,08%

Sécurité

Debt / Equity
0,28
Current Ratio2,15
Interest Coverage32,10

Valorisation

P/E Ratio
2,94
P/B Ratio0,44
EV/EBITDA-0,29
Dividend Yield0,06%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -4,97% Revenue Growth (3Y) -3,29%
Earnings Growth (1Y) 5,50% Earnings Growth (3Y) 3,90%
Revenue Growth (5Y) 2,94% Earnings Growth (5Y) 4,70%
Profitability
Revenue (TTM) 11,81B Net Income (TTM) 2,06B
ROE 14,77% ROA 8,43%
Gross Margin 65,45% Operating Margin 24,08%
Net Margin 17,45% Free Cash Flow (TTM) 2,41B
ROIC 11,99% FCF Growth (3Y) 14,65%
Safety
Debt / Equity 0,28 Current Ratio 2,15
Interest Coverage 32,10 Dividend Yield 0,06%
Valuation
P/E Ratio 2,94 P/B Ratio 0,44
P/S Ratio 0,51 PEG Ratio 1,68
EV/EBITDA -0,29 Dividend Yield 0,06%
Market Cap 6,06B Enterprise Value -830,33M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 11,81B 12,43B 12,63B 12,06B 10,52B
Net Income 2,06B 1,95B 1,91B 1,78B 1,71B
EPS (Diluted) 2,24 2,10 2,04 1,90 1,83
Gross Profit 7,73B 7,66B 8,17B 7,81B 6,85B
Operating Income 2,84B 2,42B 2,35B 2,27B 2,50B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 24,46B 25,04B 24,86B 22,37B 20,59B
Total Liabilities 9,55B 10,28B 9,93B 8,06B 6,95B
Shareholders' Equity 13,86B 14,04B 13,88B 13,00B 12,11B
Total Debt 3,93B 3,48B 3,62B 2,69B 1,93B
Cash & Equivalents 10,83B 11,33B 10,41B 9,15B 9,95B
Current Assets 16,42B 17,27B 16,99B 14,67B 14,63B
Current Liabilities 7,63B 8,09B 7,40B 6,93B 6,08B

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026